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Summary
Integrated testing strategies (ITS), as opposed to a single definitive test or fixed batteries of tests, are expected to 
efficiently combine different information sources in a quantifiable fashion to satisfy an information need, in this case for 
regulatory safety assessments. With increasing awareness of the limitations of each individual tool and the development 
of highly targeted tests and predictions, the need for combining pieces of evidence increases. The discussions that took 
place during this workshop, which brought together a group of experts coming from different related areas, illustrate 
the current state of the art of ITS, as well as promising developments and identifiable challenges. The case of skin 
sensitization was taken as an example to understand how possible ITS can be constructed, optimized and validated. This 
will require embracing and developing new concepts such as adverse outcome pathways (AOP), advanced statistical 
learning algorithms and machine learning, mechanistic validation and “Good ITS Practices”.
Keywords: in vitro methods, testing strategy, Tox21c, skin sensitization, computational toxicology
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1  Introduction 
Regulators from different agencies worldwide as well as the 
regulated scientific community in general are becoming in-
creasingly aware of the limitations of the current safety test-
ing paradigm. Animal-based high-dose testing in typically one 
stand-alone guideline test is not always relevant for human ex-
posure scenarios. New in vitro and in silico approaches, how-
ever, are limited in nature and can usually only either supple-
ment the animal test or serve as one component of a range of 
information sources that need to be combined in a relevant, 
reliable and unbiased way (Leist et al., 2014). This is exactly 
the purpose of the concept of integrated testing strategies (ITS), 
also known as integrated approaches to testing and assessment 
(IATA), with the aim to combine different pieces of informa-
tion / tests in a more mathematically efficient and biologically 
informed way. For the development of such science-based and 
human-relevant approaches for safety assessment of chemicals, 
a decision making process needs to be adopted and accepted for 
regulatory purposes. In order to better understand the mecha-
nisms and factors involved, it is now well recognized that the 
future of chemical safety assessment must move away from an-
imal tests towards a combination of complementary approaches 
(in vitro, ex vivo, in silico, in chemico) that address functional 
mechanistic endpoints tied to adverse outcomes of regulatory 
concern. In spite of this increasing shared awareness, the way 
toward this goal remains unclear. There are controversies sur-
rounding the definition of ITS, extending to how they can be 
implemented, validated and reach global regulatory accept-
ance. Results from the different tests need to be combined in 
an objective and transparent way (Kinsner-Ovaskainen et al., 
2009, 2012; Hartung et al., 2013a). 
The principle of ITS, as they are used in this context, is to 
incorporate multiple data from various information streams, 
derived from different test methods, test method batteries, 
tiered test schemes, modeling techniques such as (Q)SAR 
(quantitative structure activity relationship), kinetics, expo-
sure and epidemiological data, HTS (high throughput screen-
ing) and computational toxicology, etc. into one decision-
making process (Judson et al., 2013). In this framework, the 
role of ITS is crucial, but the way to achieve its aim is not 
straightforward. There are many challenges: to accommodate 
the flexibility ITS require, to quantify and respond to varying 
levels of uncertainty, to incorporate preexisting knowledge, 
to assess test method availability and reproducibility, to de-
fine applicability domains of ITS components or necessary 
accuracy, all with the requirements of standardization that are 
mandatory for regulatory applications.
For this reason, there is the need to develop transparent, ob-
jective and consistent ITS tools to support reliable hazard and 
risk assessments. These are the core conceptual ITS require-
ments formulated in Jaworska and Hoffmann (2010) and later 
reiterated by Hartung et al. (2013a). 
Regarding ITS, there are still many open questions:
– What are the selection criteria for in vitro and in silico meth-
ods and the combination criteria of the methodologies for 
constructing ITS?
– Which statistical and/or mathematical tools are available for 
relevant integration of data from different sources? 
– Can we adopt standards for statistical evaluation?
– How should the predictive performance of ITS be assessed 
and validated?
– How should the outcome of ITS be evaluated for regulatory 
use?
To answer these questions, a group of experts was convened, 
coming from many different areas of expertise and organizations, 
including regulatory, validation and government bodies (EFSA, 
EURL ECVAM, US NICEATM, US FDA) and scientific asso-
ciations (CEFIC, EPAA, ESTIV) (Box 1). The present report 
represents the outcome of a three-day workshop sponsored and 
co-organized by CAAT, the Doerenkamp-Zbinden Foundation 
(DZF), BASF, the International Fragrance Association (IFRA), 
the Research Institute for Fragrance Materials (RIFM) and the 
European Society of Toxicology In Vitro (ESTIV). This work-
shop was held in Ranco (Varese, Italy) on July 8-10, 2013. 
2  Background 
According to the European Chemicals regulation REACH 
(Regulation EC 1907/2006), safety assessment of a substance is 
performed through the full characterization of the risks related 
to its use and distribution, including physical hazards, toxico-
logical and ecotoxicological properties. Those are combined 
with a detailed exposure assessment for the final definition of 
the risk management measures that must be implemented for a 
reasonable safe use, or restriction, of the substance.
The idea of applying multiple testing strategies for hazard and 
safety assessment started more than twenty years ago (Basket-
ter, 1994). The reasons why a single in vitro test may hardly 
Box 1: List of acronyms of organizations with corresponding websites
Acronym	 Definition	 website
CAAt Center for Alternatives to Animal testing caat.jhsph.edu
CAAt-europe Center for Alternatives to Animal testing – europe cms.uni-konstanz.de/leist/caat-europe
CEFIC	 European	Chemical	Industry	Council	 www.cefic.org
DZF Doerenkamp-Zbinden Foundation www.doerenkamp.ch/en/?id=10
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replace a full in vivo test are explained by Natsch (2014), and 
may be summarized as follows:
1.  In vivo processes usually involve a chain of events while 
one in vitro test often represents only a single or a few steps 
of this complex process. When the outcome of that chain of 
events is toxicity, it is referred to as an adverse outcome path-
way (AOP).
2.  In vitro methods may represent not only a single event (a 
“key event” in the AOP nomenclature), but also a single 
mode of action. Different modes of action may cause the 
same toxicological effect.
3.  Different classes of chemicals may require different test 
methods, e.g., because of the limited applicability domains 
of some in vitro tests.
4.  ADME (absorption, distribution, metabolism and excretion) 
must be considered; these processes are often not well repre-
sented by current regulatory in vitro models.
5. The outcome from an in vitro test may be limited to reflect 
only a specific in vivo dose response range and more methods 
are then required to cover the full dose response range.
In spite of the common agreement that ITS hold enormous 
promise for effective assessment of toxicological properties of 
chemicals, little has been done to really apply ITS, in the sense 
of integration of both non-testing (QSAR, read across) and ex-
perimental assays. So far, there are very few tools that com-
bine the methods in an objective way, and often the scientific 
knowledge of many toxicity mechanisms is still not available 
or at least not clear enough to apply a full testing strategy that 
provides certainty that the endpoint is fully covered.
In recent years, many initiatives have started and several pa-
pers have been published that foster the application of ITS. The 
first legal implementation of the ITS concept was the approval 
of the REACH Regulation (Regulation EC 1907/2006). This 
ground-breaking legislation is the first in which the combined 
application of non-standard procedures for safety assessment 
was included in a legal text (see Annex XI). Starting from Ar-
ticle 1, there is explicit reference to the possibility of applying 
alternative methods to avoid new tests on animals. Annex XI of 
the Regulation explains how non-standard procedures can be 
used, with explicit mention of the Weight of Evidence (WoE) 
approach, defined as the conclusion derived “from several inde-
pendent sources of information leading to the assumption/con-
clusion that a substance has or has not a particular dangerous 
property, while the information from each single source alone is 
regarded insufficient to support this notion.” The concept was 
further extended in the series of guidelines that followed the 
REACH publication (http://echa.europa.eu/support/guidance), 
which explain how to use a testing strategy for each endpoint, 
e.g., how to use new tests for the definition of substance proper-
ties, and through the EU FP6 project OSIRIS that was devoted 
to developing ITS schemes for human and environmental end-
points (http://www.ufz.de/osiris). Within the scope of REACH, 
WoE can be defined as the organization of existing information 
while the set up of an ITS is the decision process that leads to 
performing new tests. 
A vast number of chemicals have been registered within 
the REACH program and if each of them were tested in vivo 
then the costs in terms of animal lives and economic resources 
eCHA european Chemical Agency echa.europa.eu
eFSA european Food Safety Authority www.efsa.europa.eu
ePA environmental Protection Agency www.epa.gov
ePAA european Partnership for Alternative Approaches to Animal testing www.epaa.eu.com
ESAC	 EURL	ECVAM	Scientific	Advisory	Committee	 see	EURL	ECVAM
eStIV european Society of toxicology In Vitro www.estiv.org
eURl eCVAM european Union Reference laboratory for alternatives to animal testing ihcp.jrc.ec.europa.eu/our_labs/ 
  eurl-ecvam
FDA Food and Drug Administration www.fda.gov
ICCVAM Interagency Coordinating Committee on the Validation ntp.niehs.nih.gov 
 of Alternative Methods
IFRA International Fragrance Association www.ifraorg.org
JaCVAM Japanese Center for the Validation of Alternative Methods www.jacvam.jp/en/
NICeAtM National toxicology Program Interagency Center for the evaluation www.niehs.nih.gov/research/atniehs/dntp/ 
 of Alternative toxicological Methods assoc/niceatm/
NIH National Institute of Health www.nih.gov
OeCD Organisation for economic Co-operation and Development www.oecd.org
RIFM Research Institute for Fragrance Materials www.rifm.org
RIVM National Institute for Public Health and the environment www.rivm.nl
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would be enormous (Hartung and Rovida, 2009; Rovida and 
Hartung, 2009). Mid 2014, about 12,500 individual substanc-
es had been registered within the scope of REACH and most 
of the data are available in a public database accessible from 
the ECHA website (http://echa.europa.eu/information-on-
chemicals/registered-substances). This database represents a 
vast resource of structured information that may feed models 
as well as offering the possibility to check the outcome of var-
ious predictions. Methods by which registrants tried to apply 
non-standard approaches are regularly reported by ECHA, the 
European Chemicals Agency (ECHA, 2014).
EURL ECVAM plays a significant role: Recently, the 3T3 
Neutral Red Uptake Cytotoxicity Assay for Acute Oral Toxicity 
received a positive opinion from the EURL ECVAM Scientific 
Advisory Committee (ESAC) for the identification of substanc-
es with an LD50 > 2000 mg/kg with the caveat that, due to the 
limitations of the test method, results should always be used in 
combination with other information sources to build confidence 
in the negative assay results. EURL ECVAM fully endorsed 
the ESAC opinion and further recommended the development 
of ITS aiming at full or at least partial identification of acute 
oral toxicity hazard according to the GHS (Categories 1 to 4) 
(http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-
recommendations/3t3-nru-recommendation). 
In the past, the area of skin and eye irritation yielded inter-
esting results with proposed strategies that may fully replace 
in vivo testing (Scott et al., 2010). EURL ECVAM organized 
a workshop on validation of ITS that gave the opportunity 
for a very interesting discussion among scientists (Kinsner-
Ovaskainen et al., 2012). It was proposed that there is no need 
for formal validation of ITS for screening purposes, for risk 
assessment purposes and for hazard classification and labelling 
unless there is an intention to replace a test in use for regula-
tory purposes. 
In response to both the new Regulation for cosmetics prod-
ucts (Regulation EC 1223/2009), which prohibits new tests on 
living vertebrate animals for cosmetic purposes, and to answer 
the demands of consumers, who are more and more responsive 
to animal welfare aspects, academia, cosmetics industries as 
well as chemical suppliers have been very active with large in-
vestments and research programs. Cosmetics Europe is now co-
funding with the European Commission the cluster of projects 
called SEURAT-1 (http://www.seurat-1.eu), which is investing 
significant resources to find how repeated dose toxicity stud-
ies can be replaced by alternative methods. This large project 
initiative combines five research projects, a central data and 
knowledge management project and a multidisciplinary coor-
dination action team, trying to integrate advanced techniques in 
the area of stem cells, microfluidic bio-reactors, in silico mod-
elling, etc. 
The application of ITS for the assessment of skin sensitiza-
tion potential of chemicals is an area of focus of EPAA (Euro-
pean Partnership for Alternative Approaches to Animal Testing, 
a voluntary collaboration between the European Commission 
and representatives from both industry and trade associations), 
with the aim of improving and implementing the 3Rs approach 
in the regulatory framework. EPAA organized two workshops 
to further elaborate how to apply testing strategies for skin 
sensitization (Basketter et al., 2013). During the ITS-focused 
EPAA workshop (September 26, 2011, Basketter et al., 2012a), 
all participants agreed on the idea that ITS was necessary to im-
prove safety assessment and not “just” a way to save animals. 
In that workshop it was also proposed to further promote the 
involvement of regulators in order to expedite acceptance of 
the new approach. Regulatory involvement may also represent 
a stimulus for the industry to use new methods as soon as pos-
sible. In fact, the subsequent EPAA workshop was hosted by 
ECHA in Helsinki (February 4, 2013), with almost 60 partici-
pants from industry, ECHA, EURL ECVAM, OECD (Box 1) 
and many European Member State representatives (Basketter 
et al., 2013).
A quantitative WoE approach has been developed through the 
OSIRIS project with ITS schemes for skin sensitization, mu-
tagenicity and carcinogenicity employing Bayesian networks 
(Buist et al., 2013; Rorije et al., 2013), keeping in mind that 
the latter is one of several opportunities for handling situa-
tions of redundant and conflicting information. Beyond aquatic 
endpoints, which are out of the scope of the present paper, the 
OSIRIS project produced interesting results in the area of re-
peated-dose toxicity (Tluczkiewicz et al., 2013) and reviewes 
opportunities for predicting physico-chemical properties in the 
regulatory context (Nendza et al., 2013). 
The above-mentioned projects and activities provide exam-
ples of developments taking place mainly in the EU. In 2007, 
the National Research Council of the US National Academy of 
Sciences published the well-known report on Toxicity Testing in 
the 21st century (NRC, 2007), which explained why the classi-
cal approach to toxicology assessment was not adequate to cope 
with present-day needs. Traditional approaches were found to 
be too time-consuming and expensive, requiring also the sacri-
fice of many animals and, worst, most in vivo studies may not 
reflect the human response. The revolution in this approach to 
toxicity testing is to investigate the possible mechanisms of ac-
tion of the chemical substances on human cells and human gene 
targets to better predict the human response. Following this con-
cept, the EPA’s ToxCast research program is testing thousands 
of chemicals in a broad array of cellular, in vitro, biochemical 
and in silico models, thereby biologically phenotyping a large 
number of substances via a huge number of endpoints (Tab. 1). 
Phase I of ToxCast tested predominantly food-use pesticides 
that already had a wealth of animal toxicity data from regula-
tory guideline studies. The results were used to create compu-
tational models to predict endpoints such as developmental and 
reproductive toxicity (Martin et al., 2011; Kleinstreuer et al., 
2011; Knudsen, 2012). Phase II and Phase III vastly expanded 
the chemical libraries to cover many untested compounds, pro-
viding the opportunity to validate the predictive signatures and 
prioritize environmental chemicals for potential hazards (http://
epa.gov/ncct/toxcast/data.html).
The work program of OECD, the umbrella organization 
for chemical testing harmonization representing 34 countries 
worldwide, is also relevant in this context. OECD work on test 
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the different pathways of toxicity (PoT) and modes of action 
(MoA) in humans. Testing is supposed to produce data that must 
be interpreted and then compared to a threshold determination 
for adversity. This approach is different from the European idea 
of first studying in detail the mode of action and then developing 
tests that mimic each step of the process. 
A constructive way to compare and combine the two ap-
proaches may lie in testing a common set of chemicals, such 
as the OECD reference chemicals developed for various test 
guidelines, and the ToxCast library. The ECHA database (http://
echa.europa.eu/web/guest/information-on-chemicals/regis-
tered-substances) is particularly useful because it contains data 
about all registered substances within the scope of the REACH 
program. Provided the data are well prepared and reliable, this 
will facilitate a better understanding of the applicability domain 
of the relevant assays.
4  Composition of ITS
The term ITS has been generally used when more than one test 
is applied in combination to characterize the toxicological ef-
fects of a substance. ITS were initially conceived with the idea 
of replacing in vivo tests, with the awareness that no single in 
vitro test can reproduce the complex interactions that occur in 
an intact organism. Some pioneering work was done by the 
ECVAM Integrated Testing Taskforce, which presented ITS 
as a combination of toxicodynamic and toxicokinetic param-
eters (Blaauboer et al., 1999). Even though that principle is 
still valid, nowadays the aim of ITS is definitely broader, with 
the ambition that ITS must help elucidate the mechanism of 
action of chemical perturbations with respect to human health 
or the environment. Ideally, ITS will be the highest quality 
source of mechanistic information for the definition of safety 
assessment.
Such evolution in the concept of ITS explains why there is 
not a unique definition and why there are many ways to com-
bine tests to build a testing strategy, as explained in Figure 1. 
The two simplest forms of ITS are a battery of tests and tiered 
strategies, as explained by Jaworska and Hoffmann (2010). 
A battery of tests is executed in parallel and generally the re-
sults of all tests are necessary for the definition of a specific 
property. In tiered strategies series of tests are applied in se-
guidelines and Good Laboratory Practice (GLP) is crucial and 
generally well accepted as a standard for regulatory purposes. 
The OECD series on testing and assessment, No.168 (OECD 
No. 168, 2012a,b) is particularly interesting as it states the pos-
sibility of approaching the assessment of an endpoint, in this 
case skin sensitization, by applying the concept of an AOP that 
represents the existing knowledge concerning the linkage be-
tween a molecular initiating event and an adverse outcome at the 
individual or population level (Ankley et al., 2010). The OECD 
idea is that combinations of mechanistically based test methods 
within IATA are needed to be able to substitute the regulatory 
animal tests currently in use. Recently, OECD published a new 
guidance document describing an IATA for skin corrosion and 
irritation (OECD No. 203, 2014). This is the first well-defined 
IATA that is being adopted by the OECD. Notably, OECD is 
also responsible for the OECD QSAR Tool Box (http://www.
qsartoolbox.org), which is freely available software that helps 
risk assessors to identify structural alerts and define groups and 
similarities among chemicals. Even though not directly focused 
on ITS, this software represents an interesting tool that can as-
sist users in building optimized ITS, and the OECD is actively 
working to further develop such aspects for IATA, in the hazard 
assessment and test guideline programs.
3  Comparison of the European and  
American approaches
ITS is a very generic term, and there are different ways in which 
ITS may be constructed, e.g., with many tests/substances cast-
ing a wide net vs. a priori network construction and assay de-
velopment. Their construction may differ also according to the 
starting point, i.e., beginning from the definition of a relevant 
endpoint (top down) or for screening a wide array of substances 
(bottom up). The EU (Basketter et al., 2012b) vs. US approach 
(Kavlock et al., 2012) reflects such a difference: The driving 
force in the EU stands on new regulations that explicitly ask for 
application of in vitro tests before performing any new in vivo 
studies, with the ultimate example being the new regulation of 
cosmetic products stipulating the complete ban of tests on living 
animals for cosmetics products and ingredients. In contrast, the 
US approach driven by Tox21c and the ToxCast project (Tab. 1) 
evaluates many chemicals on a set of assays that should address 
Tab. 1: List of work packages in the ToxCast and Tox21 HTS projects
Further details at http://www.epa.gov/ncct/toxcast/chemicals.html
Set  Chemicals  Assays  Endpoints  Completion  Available to Tox21 partners
toxCast Phase I  293  ~600  ~1100  2011  03/2013 
toxCast Phase II  767  ~600 ~1100 03/2013 10/2013
toxCast Phase IIIa 1001  ~100  ~100  ongoing  2015?
e1K (endocrine)  880  ~50  ~120  03/2013 10/2013
tox21  8,193  ~25  ~50  ongoing  ongoing
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Generally speaking, ITS should combine different building 
blocks, which can also be based on non-test (in silico and read-
across) and test methods, and the final decision about the safety 
assessment of a substance should be based on information from 
more than one type of source. 
All results acquired through the testing must have quantifi-
able confidence levels and associated uncertainties to enable 
the application of an objective probabilistic approach. Well-
developed and widely used probabilistic modeling tools are the 
Bayesian Networks (BN), whose potential in ITS framework 
was introduced by Jaworska and Hoffmann (2010), although 
other techniques are also feasible (Jaworska et al., 2013). 
Classification algorithms, such as classification and regression 
trees (CART) and random forests, were recently used to con-
struct testing strategies for acute oral toxicity testing (Kopp-
Schneider et al., 2013; Prieto et al., 2013; Kinsner-Ovaskainen 
et al., 2013).
Though it is clear that not all steps need to be measured for 
safety assessment, setting of decision points is not easy and 
depends upon how much information is required to fulfill the 
specific needs. This is highly dependent on the purpose of the 
ITS, ranging from simple hazard identification and chemical 
prioritization to a sophisticated risk assessment with increasing 
numbers of tests and levels of complexity. For example, in some 
cases the measure of chemical reactivity, e.g., with the DPRA 
(Direct Peptide Reactivity Assay), can be regarded as sufficient 
as a yes/no answer for a simple preliminary hazard categoriza-
quence, by following yes or no decisions, as is the example 
of eye irritation (Balls et al., 1999), or a chain of events, as in 
the case for skin sensitization (Maxwell et al., 2011; Van der 
Veen et al., 2014; Natsch, 2014). The most advanced Bayesian 
decision methods are based on such a tiered strategy but take 
into account the fact that test results are not perfect “yes/no” 
answers and that within this information value there is some 
uncertainty; the overall uncertainty decreases as the weight 
of the results accumulates. More generally, the ITS should be 
composed of building blocks with precise decision points that 
can halt the process when a pre-defined level of confidence 
is reached and should optimize the number of tests that are 
required accordingly. The WoE approach is usually based on 
existing data while ITS should prospectively address which as-
says need to be performed for the assessment of an endpoint 
or in general for the definition of the risk posed by the use of 
a substance. However, the ITS concept has some similarity to 
the WoE approach as it represents a way to combine different 
results to make a decision (Balls et al., 2006).
ITS are very context-dependent and multiple solutions are 
likely to be available and desirable. Explicitly, an ITS should 
contain the following elements:
1.  Information target identification;
2.  Systematic exploration of knowledge;
3.  Choice of relevant inputs;
4.  Methodology to synthesize disparate evidence;
5.  Methodology to guide testing
Fig. 1: Schemes for the different approaches that are considered as form of ITS
A,	Weight	of	Evidence	(WoE).	A	set	of	independent	assays	provides	the	same	number	of	results.	None	of	them	alone	is	sufficient	to	
make	a	decision,	but	all	together	may	lead	to	the	final	decision	on	the	endpoint.	This	approach	is	described	in	Annex	XI	of	REACH	and	
considered as acceptable from a regulatory point of view, even if none of the tests is performed in a standard way. 
B,	Battery	of	tests.	The	final	result	is	defined	by	the	sum	of	the	results	from	many	tests	that	all	must	be	performed.	This	approach	implies	
that all methods share the same applicability domain. It is considered by many scientists as the only possibility for in vitro methods to 
replace in vivo tests.
C,	Tiered	strategy.	According	to	the	results	of	the	first	step	it	is	decided	which	following	test	must	be	performed.	It	is	an	open	system	as	
there is no precise combination of tests, which may be in vitro methods or QSAR evaluations. Any of the tests can return either a number 
or a mechanistic elucidation or a yes/no answer.
The	three	schemes	are	not	always	well	separated.	In	some	cases,	not	all	tests	from	a	battery	(Fig.	1B)	are	necessary	for	the	definition	
of the endpoint, while in some cases the path of a tiered strategy (Fig. 1C) is considered mandatory, resembling more a battery of tests. 
Stopping	and	decision	making	is	triggered	when	a	predefined	knowledge	level	is	reached.
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respect to doses of the organism exposure. It is necessary to 
consider the absorption, distribution and the metabolism of the 
substance in the human organism, the metabolism and interac-
tion among organs (Yoon et al., 2012; Jacobs et al., 2013). This 
fundamental aspect is often underestimated. For example, there 
are accepted methods for the analysis of skin penetration, but 
few that consider the actual permeance of a substance in the 
epidermis, where the sensitization process starts (Basketter et 
al., 2007). In general, calculation related to the in vivo distribu-
tion of the substance and its metabolites should be considered. 
This aspect is essential to underpin the so-called quantitative in 
vivo/in vitro extrapolation (QIVIVE) (Blaauboer et al., 2012; 
Bessems et al., 2014).
The way forward for ITS is outlined in Table 2. An innova-
tive ITS should be flexible and preferably based on a proba-
bilistic approach; assays should be selected to gain the best 
balance between the number of tests (i.e., effort, time and 
resources) and information that is obtained. All single inputs, 
in chemico, in silico and/or in vitro, must be combined in a 
way that acknowledges and statistically assesses their respec-
tive contributions. Economic considerations may have to be 
considered too, as usually methods that are more complex are 
also more expensive, requiring sophisticated equipment and 
technical expertise.
ITS must be adaptive, allowing straightforward omission or 
addition of new tests as they become available or when newly 
acquired knowledge yields a more effective combination. At 
any level, the reasoning for any selection must be transpar-
ent, objective and independent of the personal judgment of the 
operators.
The statistical tools used to interpret ITS outcomes must be 
objective and able to evaluate when the acquired knowledge has 
reached a sufficient level of confidence to fit the final purpose 
and stop the process, moving from a deterministic approach 
with a preconceived belief in the ability to perfectly foresee 
the effect to a probabilistic prediction of the final outcome on 
the human population. Ideally, in the future, informatics tools 
may provide value of information analyses that identify the 
next tests to run in order to reach the final goal of optimizing 
costs, resources and predictive accuracy. Even if the BN, for 
example, is a promising informatics tool for combining the dif-
ferent components of the ITS, this methodology needs formal 
approval, and novel network learning tools may be applied to 
free the process from personal judgment. 
tion of the substance (Gerberick et al., 2007). In the context of 
the EU FP6 project ACuteTox, the estimation of the oral LD50 
dose from an effective concentration in vitro and the application 
of classification algorithms were used to predict official acute 
oral toxicity categories (Prieto et al., 2013). 
Ultimately, any ITS should be designed to fit a specific pur-
pose, by balancing the applicability domain of the tests, suf-
ficient information, cost and experimental feasibility. Using 
acute oral toxicity as an example, Norlen and colleagues (2014) 
compared the cost-effectiveness of different approaches based 
on single methods (four in silico tools and one in vitro cytotox-
icity assay) and battery combinations of methods. They nicely 
illustrated how to assess the cost-effectiveness of alternative 
methods and how to interpret the results.
Another difficulty that may arise when a combination of 
tests is proposed for the prediction of an adverse effect, comes 
from the fact that the majority of in vitro tests are developed 
independently, as “stand-alone” prediction models for hazard 
identification. Most method developers still hope to find the 
perfect in vitro method to fully replace an in vivo test, in spite 
of the fact that in reality usually a set of complementary in 
vitro tests is necessary to reflect complex endpoints. 
Each assay that contributes to building the ITS has to be well 
characterized, whether it is based on the biochemical under-
standing of the MoA, cellular effects or is related to other as-
pects that, for example, may impact the bioavailability of the 
substance. Test method definitions should include a defined 
protocol, the precise scope of the final endpoint, information on 
applicability domain and the variability of the measurements. 
The proper test selection varies according to the context of the 
testing strategies. In some applications, e.g., for cosmetics, sen-
sitivity or reliable identification of no toxicity is more impor-
tant than specificity, but this can be different for other uses of 
the substance, for example if there is relevant exposure.
The feasibility of in vitro testing may be limited; a variety 
of different tests may be necessary in order to cover the full 
chemical universe and chemical properties, for example, the 
applicability domain is limited in case of poorly water-soluble 
substances. 
The definition of the predictive capacity is even more chal-
lenging: when many results are combined, each of them brings 
its own variability with an impact on the definition of the toxic-
ity threshold.
Another fundamental aspect is the kinetics of the effect and 
the relationship between the concentrations tested in vitro with 
Tab. 2: Comparison between the possible composition of an ITS strategy that can be immediately applied and the innovative 
ITS	that	should	be	pursued	for	a	more	efficient	safety	assessment
ITS for hazard characterization (REACH) ITS for full safety assessment
Prescribed Flexible
Deterministic Probabilistic
Classification	 Fit	for	purpose
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contact with the same chemical, memory T cells are recruited to 
the site of contact. Interactions between T cells and antigen pre-
senting cells can take place in the skin, thus initializing the in-
flammatory reaction (elicitation phase). This sequence of events 
is started by the hapten, while the substance itself may represent 
a pre/pro hapten, i.e., it can be either metabolized or modified by 
any physico-chemical agent on the skin. 
This chain of events was chosen by OECD to illustrate the 
concept of AOP (OECD No 168, 2012a,b), i.e., a description 
of existing knowledge concerning the linkage(s) between a 
MIE and an adverse outcome at the individual or population 
level (Fig. 3). A specific substance can be tested with differ-
ent methods, each representing one or more steps in the AOP. 
Some of these assays are still at an early stage of development, 
while others are much more advanced in the validation process 
(Fig. 4). 
With regard to skin sensitization, existing information (in vitro, 
in vivo and/or human data) combined with in silico data (read-
across, QSARs) can be sufficient to reach a decision for the in-
tended aim, e.g., hazard identification. A possible step forward is 
a tiered approach beginning with analyzing chemical reactivity 
with the DPRA, followed by data from cell based assays, such 
as either the Keratinosens™ (Natsch et al., 2011) or the human 
Cell Line Activation Test (hCLAT, Sakaguchi et al., 2009). This 
may yield a consistent prediction and then be sufficient, or it may 
result in data conflict, requiring more testing to resolve the con-
flict and arrive at a final conclusion. Such a simple approach may 
answer the question of hazard identification, i.e., yes/no sensitiz-
ers, and continuing with other tests, by considering the migration 
of the dendritic cells or T cell reaction, may become necessary 
if better definition of the minimum threshold to trigger human 
5  The example of skin sensitization
While a broad applicability of ITS is expected for many toxico-
logical endpoints, skin sensitization was chosen here as a well-
developed example and test case of how ITS can be applied 
in practice. The biological mechanism of skin sensitization is 
well known, the concepts for replacing animal testing for this 
hazard have been developed in a series of projects (Rovida et 
al., 2013; Van Loveren et al., 2008; Maxwell et al., 2011), and 
there are many in vitro methods that are either validated or at 
an advanced state of validation, as well as a validated in vivo 
method (Local lymph node assay, LLNA) that may serve as ref-
erence (NIH, 1999). 
The chains of events that trigger the sensitization response 
are now sufficiently understood (Fig. 2). For a chemical to 
induce skin sensitization a number of events must take place 
and some of them are considered to be key events, essential for 
the adverse outcome. Physical and chemical properties of the 
substance are important as only substances of low molecular 
weight (LMW) overcome the skin barrier. As LMW substances 
are too small to cause an immunogenic reaction, chemical al-
lergens must bind to extracellular and cellular skin proteins to 
form a complete antigen (hapten binding). Protein binding is 
considered as the molecular initiation event (MIE) of the AOP. 
Following uptake of the complete antigen and in the context 
of danger signals primarily secreted by activated keratinocytes, 
dendritic cells (DC) mature and migrate via the afferent lymph 
vessels to the regional lymph nodes. In the lymph nodes, mature 
DC (expressing cell surface markers such as CD80 or CD86) 
stimulate the activation of hapten-specific responsive T cells, 
leading to the generation of Tc1 effector cells. Upon renewed 
Fig. 2: Scheme of the sequence of events that may induce skin sensitization potential
From Rovida et al. 2013
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Fig. 3: Flow diagram of the pathways associated with skin sensitization
From OeCD No 168a-b, 2012, reproduced with kind permission.
Fig. 4: Adverse outcome pathway with potential non-animal methods for contact hypersensitivity
References provide explanations on methods’ names, principles and protocols. the methods listed here are non-exhaustive and are 
meant as examples only; other methods are available and may also be applicable.
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of the mechanistic validity of the approach. Nevertheless, the 
assessment of any ITS must be rigorous, objective and trans-
parent, with scientific validity, which must fit the purpose. This 
procedure, even though not considered a formal alternative 
method validation, must be endorsed by an official organization 
to facilitate regulatory acceptance and recognition by govern-
ment institutions. 
For that purpose, some specific rules need to be defined. First, 
each test of the strategy must be standardized, with assessment 
regarding reproducibility and transferability of the protocol 
with a clear definition of the applicability domain and the un-
certainty of the measurement. Moreover, the type of informa-
tion that each method delivers should be clear, whether it is to 
demonstrate a mechanistic action, a physico-chemical property, 
or to elucidate a PoT or AOP. As ITS are inherently evolutionary 
(i.e., undergoing constant refinement over time), the scientific 
validity of the approach needs to be ensured, where applicable, 
with a regular peer-review process. 
A problem arises when the final performance of an ITS has no 
defined parameters and references for comparison, as is the case 
for complex endpoints such as neurotoxicity or reproductive tox-
icity. In those cases, a step-by-step procedure may represent the 
solution. The precise definition of the endpoint and the mecha-
nistic drivers is the first step, followed by a proposed description 
of the AOP. The knowledge of the in vivo mechanism is essential 
even though it is not necessary that each and every step of the in 
vivo process is represented by a test. The opposite is true, i.e., the 
mechanistic relevance of the specific assay must be defined to-
gether with the demonstration that it fits the purpose in the strat-
egy, which should be clearly defined, whether it is for hazard, for 
potency or for the identification of a single PoT. 
Validation is based on the reproducible and accurate response 
of the strategy when challenged with a set of chemicals with 
well-known characteristics and therefore the reference chemical 
selection is essential for a successful process. Those chemicals 
must have a broad array of structural characteristics in terms of 
physical and chemical properties, e.g., octanol/water partition 
coefficient (Kow), mechanism / mode of action (if known) plus 
toxicological behavior that should include the whole range of 
activity with both positive and negative controls. The compila-
tion of a set of reference standards can be useful as exemplified 
for sensitization (Casati et al., 2009; Kolle et al., 2013) as the 
starting point for the development of new methods or for the 
comparison of two equivalent methods. Extensive validation 
will still require a larger number of chemicals. Active consul-
tations with statisticians is important to decide on the proper 
number of chemicals and datasets needed to have statistically 
sufficient power, considering prevalence but also the purpose of 
the strategy (Kopp-Schneider et al., 2013). At this moment this is 
probably the main constraint, because the list of chemicals with 
known toxicological profiles really relevant to humans is very 
limited. Most of the time, only results from animal studies are 
reaction is required or to distinguish between skin and respira-
tory sensitizers (Rovida et al., 2013). Mathematical models have 
been proposed to quantitatively establish a relationship between 
the dose of sensitizer applied to the skin and the possible human 
adverse effect (Maxwell et al., 2014).
Recently, EURL ECVAM published its recommendation on 
the DPRA1 and the Keratinosens™2 assays; for hCLAT also a 
DB-ALM (EURL ECVAM DataBase service on ALternative 
Methods) protocol was published by ECVAM3. The perform-
ance of each method is measured in isolation, with its own re-
producibility, reliability and relevance assessment, to ensure 
that it will be sufficiently robust for test guideline development. 
Accuracy has been calculated for the set of chemicals tested as a 
preliminary evaluation only. Recent OECD documents (OECD 
No. 168, 2012a,b) explain which methods will enter the strat-
egy, and an ITS for skin sensitization is being finalized. Because 
the OECD membership is comprised of many different regula-
tory frameworks, precise instructions as to how to quantitatively 
integrate the results may need flexibility, depending upon the 
regulatory jurisdiction. 
It has been demonstrated (Bauch et al., 2012; Natsch et al., 
2013; Van der Veen et al., 2014) that the proper and appropriate 
combination of those methods may increase the final predictiv-
ity with respect to skin sensitization hazard identification, and 
that this approach may even exceed the accuracy of the LLNA. 
Also, potency estimates for skin sensitization from ITS have 
been presented (Jaworska et al., 2013). This was possible be-
cause many chemicals are well characterized with regard to 
their sensitization properties. In future this can be even further 
expanded by considering the corresponding human response 
(Basketter et al., 2014). While highlighting the importance of 
defining a set of reference substances for ITS development, this 
fact also highlights the difficulties in compiling a proper list of 
reference substances for other endpoints, such as reproductive 
toxicity, (developmental)neurotoxicity (Smirnova et al., 2014) 
and so on, when only in vivo animal data are available.
6  Validation of ITS
Validation of alternative methods usually refers to the modu-
lar approach introduced by Hartung et al. (2004). Traditionally, 
the validation procedure is based on the evaluation of a single 
method in comparison to the traditional method, which is con-
sidered as a reference standard. Validation of in vitro methods is 
now undertaken by EURL ECVAM in the EU and by ICCVAM 
(Box 1) in the US, with important contributions from JaCVAM 
(Box 1) in Japan and other OECD member countries, under the 
auspices of the OECD. 
Establishing precise rules for ITS validation may be complex, 
as the ITS itself is a dynamic process that cannot be defined by 
strict rules and may in fact be designed to provide an evaluation 
1 http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-recommendations/eurl-ecvam-recommendation-on-the-direct-peptide-reactivity-assay-dpra
2 http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-recommendations/recommendation-keratinosens-skin-sensitisation
3 http://ecvam-dbalm.jrc.ec.europa.eu/view_doc.cfm?iddoc=1558&tdoc=prot
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First of all, each single component of an ITS has to be de-
fined. The purpose of each test must be clear, the protocol 
precise, and its robustness and variability must be carefully 
quantified. Even if each of those steps has to be adapted to the 
specific test, the general principle of scientific evidence has to 
be preserved.
Those pre-requisites can be immediately applied when rigid 
tiered strategies are used by combining validated test methods, 
as is done, for example, for eye irritation (EPA, 2009), acute 
oral toxicity (Prieto et al., 2013) or more recently for develop-
mental toxicity (Sogorb et al., 2014) and reproductive toxicity 
(Piersma et al., 2013), even though these are still at a proposal 
stage. Despite the large investment of time and resources toward 
providing a straightforward and transparent approach, even the 
case of skin sensitization is complex, with the ambition of com-
bining tests for bioavailability, mechanistic elucidation, reactiv-
ity and potency. 
Beyond assessing the validity of each single test, the whole 
procedure must have precise and objective characteristics for 
regulatory acceptability. It can be imagined that in the future, 
ITS will probably define the overall safety assessment of a sub-
stance, rather than the single effect, such as skin sensitization, 
acute systemic toxicity, developmental toxicity and so on.
From the perspective of ideal ITS as shown in Figure 5, the 
final results must be independent from any subjective interpre-
tation. This can be achieved by setting minimum requirements 
for an ITS tool. However, the necessity for precision, objectivity 
and reproducibility of the ITS should not impair the necessary 
characteristic of ITS adaptability. Adaptability of ITS includes 
the possibility of introducing new tests whenever available and 
to adapt the ITS to the specific purpose for which it is applied. 
In fact, the end of the process is defined by the purpose and this 
can range from mechanistic elucidation to hazard identification 
available, and the relevance in translating these studies to human 
biology is generally questionable. 
The applicability domain of the ITS must also receive special 
attention, being derived from the overlap of the applicability do-
mains of each single assay composing the strategy. Foreseeing 
exchangeable building blocks may also help to enlarge the appli-
cability domain of the whole strategy, for example by including 
different assays for either water or non-water soluble materials.
The definition of the predictive capacity is definitely more 
challenging for several reasons. In particular, an ITS aims to 
give an answer as to the final effect rather than simply attempt-
ing to reproduce the performance of an animal test. However, 
the desired predictivity should be defined according to the final 
use (e.g., cosmetic or industrial chemicals, drugs, pesticides, 
etc.) and the effect that it is intended to predict, whether it is 
for hazard identification, classification and labelling, potency or 
even the capacity to exclude a specific risk. 
Another difficulty lies in the mathematical combination of 
tests that return many different types of results, ranging from 
binary outcomes to multi-dimensional continuous results, and 
ultimately to the explanation of a mechanism. The analysis of 
many chemicals with known behavior is fundamental but not 
always possible. While there is much data on sensitization, data 
is sparse for other endpoints such as reproductive toxicity or 
neurotoxicity. In this sense, the validation of the mechanism 
is preferable to a validation based on the final results obtained 
with single chemicals (Hartung et al., 2013b).
Finally, yet importantly, the evaluation of the robustness of 
the strategy is essential. This can be achieved through the re-
quirement that each test must meet specific minimum intra- and 
inter-laboratory reproducibility, which need to be known and 
integrated in the strategy. A combination of the building blocks 
may influence the overall robustness of the strategy, considering 
that the uncertainty of the measure may propagate when more 
methods are included. The final uncertainty is not only a mat-
ter of propagation of the error of each test; more careful and 
comprehensive sensitivity analyses are needed. Each assay may 
have a unique and variable impact on the final outcome and pro-
vide information that may range from dichotomous to continu-
ous. For this reason, a straightforward approach is preferable 
considering that unambiguous definitions may clear the way for 
regulatory acceptance.
A good tool to guide the process is provided by the principles 
of evidence based toxicology (EBT) with calls for transparency, 
objectivity and consistency of approaches (Hoffmann and Har-
tung, 2006; Guzelian et al., 2005). 
7  Discussion
In spite of the awareness of the scientific community of the need 
for ITS as a tool for safety assessment, its full applicability is 
still constrained by several factors including lack of agreement 
on the approach, testing methods that are not developed for the 
purpose and the lack of a validation procedure for regulatory 
acceptance. To overcome these difficulties, some precise pre-
requisites must be defined.
Fig. 5: Scheme for an optimal ITS
each step should be ruled by precise and objective decisions. 
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non-standard methods, some sort of adjustment to combine the 
results should be applied. Currently, this is typically based on 
expert judgment that can evaluate the validity of the data based 
on the available information. As more and more analyses are 
performed according to strict quality criteria, this will allow 
more independent and objective evaluations.
5) A mechanistic interpretation, if possible
Mechanistic interpretation is the key to accepting non-standard 
methods that usually lack points of reference. The mechanistic 
interpretation is commonly linked to the experimental protocol 
that is supposed to elucidate the specific PoT rather than the 
whole ITS. ITS based on a fully defined sequence of an AOP are 
most promising, i.e., they best reflect the key events of the AOP 
step by step through singular in vitro/in silico methods.
If these five principles are applied, the quality of the final ITS 
will be unquestionable. However, it should be recognized that 
we are currently working in an intermediate situation, where 
there is the need to apply ITS even though in some cases they 
are still under development. 
Regarding ITS execution, a quality system should be imme-
diately implemented in addition to the experimental work. The 
concepts presented here lay the framework for defining a set of 
procedures that constitute Good ITS Practice (GIP), similar to 
what has been done for Good Laboratory Practice (GLP), Good 
Manufacturing Practice (GMP), Good Cell Culture Practice 
(GCCP), etc. The concept of GIP was not extensively discussed 
during the workshop and it will not be further expanded here.
8  Conclusions and recommendations
The route toward ITS for hazard and risk assessment is still long 
and difficult, with undefined conditions for success. In spite of 
that, some steps should be immediately implemented:
1. Establishment of an international task force
It is evident that the scientific community is pursuing different 
approaches. Probably, the largest difference is between the US, 
where the approach of Tox21c has mainly resulted in large data 
generation and data-mining aims to identify the most informa-
tive tests (ultimately for ITS), and the EU where there is the 
aim to fully reproduce in vitro the steps that lead to an adverse 
outcome in vivo. As is always the case, both approaches have 
advantages and drawbacks. The creation of a supranational task 
force may improve the dialogue to inform and benefit from each 
approach, by also exploiting the results obtained on both sides. 
It is very important to communicate while being open minded 
to accept improvements, wherever they come from. We pro-
pose to create a transatlantic task force that regularly meets to 
discuss the improvements and helps to implement the lessons 
learnt overseas.
to a full definition of complex endpoints for specific regulatory 
purposes.
Learning from the example of QSAR in regulatory use, the 
principle for validation was defined by OECD through 5 prin-
ciples4:
1)  a defined endpoint
2)  an unambiguous algorithm
3)  a defined domain of applicability
4)  appropriate measures of goodness-of-fit, robustness and pre-
dictivity
5)  a mechanistic interpretation, if possible
The same principle could be translated to ITS validity, with 
some adjustments of the concepts. It should be remembered that 
a QSAR approach may be one of the components of the ITS and 
as such it must follow the principles defined by OECD.
The list below tries to develop conceptual requirements for 
ITS, some of them already formulated in Jaworska and Hoff-
mann (2010):
1) A defined endpoint
The intent of a defined endpoint in the scope of QSAR should 
be translated to a clearly defined purpose when referring to ITS, 
with the awareness that more than one route is possible to get to 
the same result. Regarding ITS, the concept of a defined purpose 
is more relevant than the endpoint. This is very important as any 
ITS may have different levels of complexity in accordance with 
the intended outcome. The defined purpose is necessary for the 
decision on when the ITS process can stop.
2) An unambiguous algorithm
The algorithm that is applied to combine the different compo-
nents of the ITS must be transparent and reproducible with de-
fined tracking of any changes. The informatics and statistical 
tools that are applied to get to a final decision must be clearly 
identifiable through proper and accessible documentation. Com-
pared to QSAR, the algorithm for ITS has another dimension of 
complexity as it requires adaptability to incorporate results from 
new tests with minimal delay in adopting new approaches. The 
respective software programs should include transparent and 
documented decision rules.
3) A defined domain of applicability
Each test of the ITS must have a defined applicability domain. 
The final result should always be within the limitation posed by 
each component. The concept of an applicability domain should 
be enlarged to include the purpose of the ITS in addition to the 
simple decision whether a specific chemical belongs to the ap-
plicability domain of the set of tests.
4) Appropriate measures of goodness-of-fit, robustness  
and predictivity
This requirement is common to all scientific experimental pro-
cedures. In the case of using existing data, possibly derived from 
4 http://www.oecd.org/env/ehs/risk-assessment/37849783.pdf
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longs to relatively few experts, while the majority of risk asses-
sors are still anchored to the traditional approach. Teaching the 
principles of ITS should be widely disseminated in universities 
together with the organization of practical training courses. At 
the moment there are many initiatives but they all rely upon the 
personal drive of certain individuals. A more harmonized and 
widespread program should be established to achieve a com-
mon understanding.
As a conclusion of the workshop, it is clear that much work is 
needed to reach the goal of completely replacing animal test-
ing with integrated and mechanistically based testing strategies. 
There was, however, agreement that the fundamental elements 
are in place. Toxicologists agree on the general focal principles 
and efforts needed to develop precise sets of guidelines and 
practical tools that enable applicability of ITS for safety assess-
ment.
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aid of bio-statisticians. The relevant structural diversity of the 
chemicals selected needs to be carefully considered at both the 
biological and computational model level.
4. Mechanistic validation
At the moment, mechanistic validation is the only proposed 
scientifically rigorous possibility to overcome the problem of 
traditional validation vs. non-validated and non-relevant animal 
models. Validation of ITS should move towards a mechanistic 
validation to demonstrate that the crucial mechanism causing 
the damage to human health as a consequence of the action of 
a xenobiotic is reflected. Mechanistic validation is the answer, 
even though details about how to apply it are not yet defined, 
representing another subject for discussion among experts.
5. Set up Good ITS Practices (GIP)
For quality assurance, GIP should be the very first step towards 
setting the rules for ITS creation and implementation, creating a 
common language that will tremendously improve data-sharing 
and acceptability. A team of experts should define a list of rules 
for GIP, following evidence-based principles. It can thereby be-
come a scientific assessment paving regulatory acceptance. Part 
of GIP should be the establishment of a standardized method to 
record and track versions of the IT tools that are applied, listing 
all variations and improvements.
6. Training and education
Training and education are always central to the adoption of 
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